Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
基本信息
- 批准号:10612967
- 负责人:
- 金额:$ 63.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-15 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:ALS patientsAmyotrophic Lateral SclerosisAnimal ModelAxonBiologicalBiological AssayBiological MarkersBloodC9ORF72CategoriesCerebrospinal FluidCharacteristicsClinicalClinical DataClinical TrialsComplexCoupledDataDecision MakingDevelopmentDipeptidesDiseaseDisease ProgressionDoseElectrophysiology (science)Eligibility DeterminationEnrollmentEnsureExtracellular DomainFDA approvedFoundationsFutureGoalsHeterogeneityIndividualInfrastructureInvestigational TherapiesKnowledgeLaboratoriesLeadLightLiquid substanceLiteratureMutationNGFR ProteinNerve Growth Factor ReceptorsNeurodegenerative DisordersNoiseOutcome MeasurePatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacodynamicsPhasePhase II Clinical TrialsPhase III Clinical TrialsPhenotypePhosphorylationPopulationProcessPrognosisPrognostic MarkerProteinsPublishingResourcesRiluzoleSamplingSignal TransductionSourceStandardizationStratificationTherapeutic AgentsTherapeutic EffectTherapeutic InterventionTimeValidationbiobankbiomarker validationcandidate markerclinical developmentclinical outcome measurescohortcomparison controldisease heterogeneitydisease natural historydrug developmenteffective therapyempowermentfollow-upgenome sequencinginclusion criteriaindividual patientneurofilamentneuroimagingpatient populationpatient stratificationpharmacodynamic biomarkerphase II trialphase III trialphenylmethylpyrazolonepost-marketpre-clinicalprognostic valuerepositoryresponsestudy populationsuccesstherapeutically effectivetooltool developmenttreatment effecturinaryvalidation studieswhole genome
项目摘要
Developing effective therapies for ALS patients has proven to be extraordinarily challenging. The reasons are many and complex, but dominant amongst these are the phenotypic heterogeneity of the ALS patient population and the insensitivity of clinical outcome measures to therapeutic effect during phase II clinical trials. The result is that it is very difficult to make well informed go/no-go decisions at the end of phase II with respect to which drugs to move forward into phase III clinical trials. Specific types of biomarkers are widely believed to hold great promise in helping to overcome these barriers. Prognostic biomarkers that help to predict the course of disease by adding value to what can be determined from readily available clinical parameters, might be used as eligibility or stratification criteria to ensure more homogeneous study populations within which treatment effect may be more readily demonstrable. Biomarkers whose longitudinal trajectory (and variability) is well defined have the potential to serve as pharmacodynamic biomarkers of treatment effect. Showing for example, that an experimental therapeutic leads to normalization of a biomarker level, would provide supportive evidence for the therapeutic effect of an experimental compound and help to empower decisions to advance the particular therapeutic agent into the next phase of clinical development. Intense discovery efforts over the course of the last 10+ years have yielded a plethora of biomarker candidates, but none of these have yet been validated in a multi-center fashion. In this project we aim do close this knowledge gap by undertaking a multi- center validation study of the lead biological-fluid-based biomarker candidates – urinary p75 neurotrophin receptor extracellular domain (p75ECD), blood and cerebrospinal fluid (CSF) phosphorylated neurofilament heavy (pNfH), blood and CSF neurofilament light (NfL) and, in the population with a C9orf72 hexanucleotide repeat expansion, peripheral blood mononuclear cell (PBMC) and CSF levels of the dipeptide repeat protein poly(GP). To accomplish the proposed aims of validating these biomarkers, we will leverage the ongoing activities of the CReATe Consortium through which ~500 ALS patients will be deeply phenotyped longitudinally, undergo whole genome sequencing, and from whom a relevant set of biological fluids are being collected and stored.
为ALS患者开发有效的治疗方法已被证明是非常具有挑战性的。原因很多且复杂,但其中最主要的是ALS患者群体的表型异质性和II期临床试验期间临床结果测量对治疗效果的不敏感性。其结果是,在II期结束时,很难就哪些药物进入III期临床试验做出明智的决定。人们普遍认为,特定类型的生物标志物在帮助克服这些障碍方面有很大的希望。预后生物标志物有助于通过增加可从现有临床参数确定的值来预测病程,可用作合格性或分层标准,以确保更同质的研究人群,在这些人群中治疗效果可能更容易得到证实。纵向轨迹(和变异性)明确的生物标志物有可能作为治疗效果的药效学生物标志物。例如,表明实验治疗导致生物标志物水平的正常化,将为实验化合物的治疗效果提供支持性证据,并有助于做出决策,以将特定治疗剂推进到下一阶段的临床开发。在过去的10多年里,密集的发现工作已经产生了大量的生物标志物候选者,但这些候选者都没有以多中心的方式得到验证。在该项目中,我们的目标是通过对主要的基于生物流体的生物标志物候选物-尿p75神经营养因子受体胞外结构域(p75 ECD)、血液和脑脊液(CSF)磷酸化神经丝重链(pNfH)、血液和CSF神经丝轻链(NfL)进行多中心验证研究来缩小这一知识差距,并且在具有C9 orf 72六核苷酸重复扩增的人群中,外周血单个核细胞(PBMC)和CSF中二肽重复蛋白聚(GP)水平。为了实现验证这些生物标志物的拟议目标,我们将利用CReATe联盟正在进行的活动,通过这些活动,将对约500名ALS患者进行纵向深度表型分析,进行全基因组测序,并从他们那里收集和储存一组相关的生物液体。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations.
- DOI:10.1093/braincomms/fcad287
- 发表时间:2023
- 期刊:
- 影响因子:4.8
- 作者:
- 通讯作者:
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice.
肌萎缩侧索硬化症神经丝轻链的生物标志物鉴定:理论与实践。
- DOI:10.1002/ana.26860
- 发表时间:2024
- 期刊:
- 影响因子:11.2
- 作者:Benatar,Michael;Ostrow,LyleW;Lewcock,JosephW;Bennett,Frank;Shefner,Jeremy;Bowser,Robert;Larkin,Paul;Bruijn,Lucie;Wuu,Joanne
- 通讯作者:Wuu,Joanne
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Benatar其他文献
Michael Benatar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Benatar', 18)}}的其他基金
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
10410344 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
10201771 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
10593638 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
University of Miami NeuroNEXT Trial Site
迈阿密大学 NeuroNEXT 试验网站
- 批准号:
9980517 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10237152 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
Clinical Centers for the NINDS NeuroNEXT(Network of Excellence in Neuroscience Clinical Trials) Consortium
NINDS NeuroNEXT(神经科学临床试验卓越网络)联盟的临床中心
- 批准号:
10744345 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10469619 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏
- 批准号:
10001608 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
多中心 ALS 生物标志物验证研究 (CReATe Biomarkers)
- 批准号:
9923007 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial; Administrative Supplement
症状前家族性 ALS (Pre-fALS) 研究 - 治疗试验的前奏;
- 批准号:
10363844 - 财政年份:2018
- 资助金额:
$ 63.09万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 63.09万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 63.09万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 63.09万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 63.09万 - 项目类别:
Operating Grants